How many institutional investors hold ABUS?

2 tracked institutional investors disclosed a position in ABUS (ARBUTUS BIOPHARMA CORP) in their most recent 13F filing.

Who is the largest institutional holder of ABUS?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in ABUS, valued at $4M.

Where does this ABUS ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

ABUS — ARBUTUS BIOPHARMA CORP

Name: ARBUTUS BIOPHARMA CORP (ABUS) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About ARBUTUS BIOPHARMA CORP (ABUS)

ARBUTUS BIOPHARMA CORP (ABUS) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $4M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in ABUS

100

/100

Strong Institutional Accumulation

Added / Increased3

Reduced0

Exited0

BearishBullish

Crowded Trade Score™

How many top investors track ABUS

/100

Undiscovered

2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded

151015+

ABUS Ownership Composition

How ARBUTUS BIOPHARMA CORP is held across tracked investor types, based on reported 13F positions.

Dominant Type

Other

100% of tracked value

Institutions

tracked investors

Total Reported

$6.4M

combined 13F value

Other100.0%

Other(2)

100.0%

Tracked investors reporting ABUS

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	785.2K	$3.5M	0.00%	Mar 31, 2026
Izzy Englander	Millennium Management	642.4K	$2.9M	0.00%	Mar 31, 2026

Ken GriffinMar 31, 2026
Citadel Advisors
Shares
785.2K
Value
$3.5M
% Portfolio
0.00%
Izzy EnglanderMar 31, 2026
Millennium Management
Shares
642.4K
Value
$2.9M
% Portfolio
0.00%

Recent activity

Investor	Action	Δ %	Current value	Filing date
Izzy Englander	New	—	$2.9M	May 15, 2026
Ken Griffin	New	—	$3.5M	May 15, 2026
Ken Griffin	New	—	$1.3M	Nov 14, 2025

Izzy Englander
New
$2.9MMay 15, 2026
Ken Griffin
New
$3.5MMay 15, 2026
Ken Griffin
New
$1.3MNov 14, 2025

Frequently asked questions

How many institutional investors hold ABUS?: 2 tracked institutional investors disclosed a position in ABUS (ARBUTUS BIOPHARMA CORP) in their most recent 13F filing.
Who is the largest institutional holder of ABUS?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in ABUS, valued at $4M.
Did institutional ownership of ABUS increase or decrease?: Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 fully exited ABUS.
Where does this ABUS ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.